Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors

Author:

Lee Eun Mi1,Jiménez-Fonseca Paula2,Galán-Moral Rocio3ORCID,Coca-Membribes Sara4ORCID,Fernández-Montes Ana5ORCID,Sorribes Elena1ORCID,García-Torralba Esmeralda6ORCID,Puntí-Brun Laura7,Gil-Raga Mireia8,Cano-Cano Juana3,Calderon Caterina1ORCID

Affiliation:

1. Faculty of Psychology, University of Barcelona, 08007 Barcelona, Spain

2. Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, 33011 Oviedo, Spain

3. Department of Medical Oncology, Hospital General Universitario de Ciudad Real, 13005 Madrid, Spain

4. Department of Medical Oncology, Hospital Universitario de Canarias, 38320 Tenerife, Spain

5. Department of Medical Oncology, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, Spain

6. Department of Medical Oncology, Hospital Universitario Morales Meseguer, 30008 Murcia, Spain

7. Department of Medical Oncology, Consorcio Sanitario del Maresme, 08304 Mataró, Spain

8. Department of Medical Oncology, Hospital General Universitario de Valencia, 46014 Valencia, Spain

Abstract

The purpose of the study was to identify subgroups of advanced cancer patients who experienced grade 3–4 toxicities as reported by their oncologists as well as identify the demographic, clinical, and treatment symptom characteristics as well as QoL outcomes associated with distinct profiles of each patient. A prospective, multicenter, observational study was conducted with advanced cancer patients of 15 different hospitals across Spain. After three months of systemic cancer treatment, participants completed questionnaires that evaluated psychological distress (BSI-18), quality of life (EORTC QLQ-C30) and fatigue (FAS). The most common tumor sites for the 557 cancer patients with a mean age of 65 years were bronchopulmonary, digestive, and pancreas. Overall, 19% of patients experienced high-grade toxicities (grade 3–4) during treatment. Patients with recurrent advanced cancer, with non-adenocarcinoma cancer, undergoing chemotherapy, and a showing deteriorated baseline status (ECOG > 1) were more likely to experience higher toxicity. Patients who experienced grade 3–4 toxicities during cancer treatment had their treatment suspended in 59% of the cases. Additionally, 87% of the patients had a dose adjustment or a cycle delayed in their treatment due to a high risk of dying during treatment. Future research should focus on identifying interventions to reduce high-grade toxicities and improve quality of life in cancer patients.

Funder

FSEOM

AstraZeneca

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3